News

Forest's planned acquisition of Aptalis will enhance its business in gastrointestinal and cystic fibrosis therapies.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

FDA releases guidance on developing drugs for the treatment of community-acquired bacterial pneumonia.

Ron Piervincenzi to assume leadership of the United States Pharmacopeial Convention on Feb. 1, 2014.

EMA has launched a new version of the EudraGMDP database, which includes the publication of statements of non-compliance with good manufacturing practice.

GE acquires Thermo Fisher's HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

A monkey-vaccine study provides insight into HIV research.

Roche?s Brain Shuttle technology transfers antibodies through the BBB.

Mac Process will merge with Schenck AccuRate and combine their operations under the name of Schenck Process.

Janssen's donation program will improve access to the company's approved HIV medicines for children and adolescents in sub-Saharan Africa.

Former US President Jimmy Carter and Pfizer commemorate the 15th anniversary of the International Trachoma Initiative to end blinding trachoma by the year 2020.

The Bristol-Myers Squibb Foundation is awarding 10 grants to fund programs for veterans and their families.

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Abrams Royal Pharmacy is recalling all unexpired lots of sterile products dispensed in the US.

Baxter International recalls dextrose injection and four sodium chloride injections.

Supernus Pharmaceuticals receives FDA approval of Orenitram for the treatment of pulmonary arterial hypertension.

This month, healthcare leaders from six of the world's top 20 pharmaceutical companies met together in collaboration with the Oliver Wyman Health Innovation Center to explore the industry's changing role in today's value-basaed healthcare structure.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Encap will collaborate with Lipocine to manufacture Lipcine's oral testosterone product, LPCN 1021, for Phase III clinical trials.

Bind Therapeutics amends its development and commercialization collaboration agreement with Amgen.

A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a ?660,000 grant from UK-based Technology Strategy Board.

Everett Laboratories acquires Quinnova Pharmaceuticals, a specialty pharmaceutical company.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

Metrics appoints a new vice-president to manage and expand its fee-for-service operations.